Education
About Us
Working with TipRanks
Follow Us
Cero Therapeutics Holdings, Inc. (CERO)
:CERO
CERO Stock Chart & Stats
$0.07
-$1.53(-29.25%)
At close: 4:00 PM EST
$0.07
-$1.53(-29.25%)
Day’s Range― - ―
52-Week Range$0.05 - $205.18
Previous Close$3.66
Volume998.67K
Average Volume (3M)1.17M
Market Cap
$1.90M
Enterprise ValueN/A
Total Cash (Recent Filing)$2.02M
Total Debt (Recent Filing)$931.02K
Price to Earnings (P/E)―
Beta-0.78
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-38.99
Shares Outstanding21,102,670
10 Day Avg. Volume288,538
30 Day Avg. Volume1,172,493
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-7.65
Price to Sales (P/S)0.00
P/FCF Ratio-2.50
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$0.10Price Target Upside42.86% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-6.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Capital And Financial StrategyCERo expects to have capital for several months, which is crucial for the continued clinical development of its CAR therapy, CER-1236.
Clinical DevelopmentCERo's CER-1236 modified T cells employ the extracellular domain of TIM-4, potentially mitigating cytokine release syndrome and neurotoxicity seen in traditional CAR-T therapies.
Safety ProfileNo safety issues reported so far, with one patient in the first cohort cleared for dose intensification, indicating a positive safety profile.
Bears Say
Price Target ReductionThe net effect of factoring in dilution and associated changes reduces the price target to $15, from $60.
Stock DelistingThe Hold rating is maintained based on the delisting of CERO shares from NASDAQ.
Stock Rating DowngradeCERO shares were downgraded to Hold from Buy following the announcement that they were to be delisted.
CERo Therapeutics Holdings News
CERO FAQ
What was Cero Therapeutics Holdings, Inc.’s price range in the past 12 months?
Cero Therapeutics Holdings, Inc. lowest stock price was $0.05 and its highest was $205.18 in the past 12 months.
What is Cero Therapeutics Holdings, Inc.’s market cap?
Cero Therapeutics Holdings, Inc.’s market cap is $1.90M.
When is Cero Therapeutics Holdings, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Cero Therapeutics Holdings, Inc.’s earnings last quarter?
Currently, no data Available
Is Cero Therapeutics Holdings, Inc. overvalued?
According to Wall Street analysts Cero Therapeutics Holdings, Inc.’s price is currently Undervalued.
Does Cero Therapeutics Holdings, Inc. pay dividends?
Cero Therapeutics Holdings, Inc. does not currently pay dividends.
What is Cero Therapeutics Holdings, Inc.’s EPS estimate?
Cero Therapeutics Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cero Therapeutics Holdings, Inc. have?
Cero Therapeutics Holdings, Inc. has 21,102,670 shares outstanding.
What happened to Cero Therapeutics Holdings, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cero Therapeutics Holdings, Inc.?
Currently, no hedge funds are holding shares in CERO
Company Description
Cero Therapeutics Holdings, Inc.
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
CERO Stock 12 Month Forecast
Average Price Target
$0.10
▲(42.86% Upside)
Technical Analysis
Theriva Biologics
―
GT Biopharma
―
Revelation Biosciences
―
Dermata Therapeutics
―
Psyence Biomedical
―